Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Basal Cell Carcinoma (BCC) of the Skin, of the Morpheiform, Infiltrative, and Noduloulcerative Types in Inoperable Patients and Not Suitable for Radiotherapy Using Formulated Methylene Blue

NCT07311070 is registered in ClinicalTrials.gov with Daryoush Hamidi Alamdari, PhD as lead sponsor.

NCT NCT07311070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07311070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Basal Cell Carcinoma (BCC) of the Skin, of the Morpheiform, Infiltrative, and Noduloulcerative Types in Inoperable Patients and Not Suitable for Radiotherapy Using Formulated Methylene Blue
Lead sponsor
Daryoush Hamidi Alamdari, PhD
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
October 21, 2025
Completion date
January 20, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced basal cell carcinoma (bcc), infiltrative basal cell carcinoma, inoperable disease, morpheaform basal cell carcinoma, noduloulcerative basal cell carcinoma